
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

